

Applicants : KING et al.
USSN : 10/593,217
Filed : September 15, 2006
Examiner : Krishnan Ganapathy
Page : 3

Atty. Dkt. No. : 891-A-PCT-US
Art Unit : 1623
Date of office action: December 3, 2008
Date of response : March 3, 2009

Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-33. (canceled)

34. (Currently amended) A composition comprising ~~an amount of a~~ dosage of 5 mg/kg to 10 mg/kg of 1,2-Bis-(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)-hydrazine (VNP40101M) and ~~an amount of a~~ dosage of about 50 mg/kg of cytarabine, wherein the VNP40101M and cytarabine produce synergistic effects when used in combination in treating tumor.

35. (Currently amended) A composition comprising ~~an amount of a~~ dosage of 5 mg/kg to 10 mg/kg of VNP40101M and ~~an amount a~~ dosage of about 70 mg/kg of fludarabine, wherein the VNP40101M and fludarabine produce synergistic effects when used in combination in treating tumor.

36. (Currently amended) A method of treating tumor in a subject, comprising the step of administering to the subject ~~an effective amount~~ 5 mg/kg to 10 mg/kg of VNP40101M and ~~an effective amount of~~ about 50 mg/kg cytarabine, wherein the amounts of VNP40101M and cytarabine administered provide a reduction in tumor growth that is larger than that achieved by administering either VNP40101M or cytarabine individually.

37. (Previously presented) The method of claim 36, wherein the tumor is solid malignant tumor, leukemia or lymphoma.

Applicants : KING et al.
USSN : 10/593,217
Filed : September 15, 2006
Examiner : Krishnan Ganapathy
Page : 4

Atty. Dkt. No. : 891-A-PCT-US
Art Unit : 1623
Date of office action: December 3, 2008
Date of response : March 3, 2009

38. (Previously presented) The method of claim 36, wherein VNP40101M and cytarabine are administered concurrently or sequentially.
39. (Previously presented) The method of claim 36, wherein VNP40101M and cytarabine are administered intravenously, subcutaneously, or orally.
40. (Previously presented) The method of claim 37, wherein the leukemia is acute myelogenous leukemia.
41. (Previously presented) The method of claim 36, wherein VNP40101M is administered between 100 and 1000 mg/m² and cytarabine is administered between 500 and 5000 mg/m².
42. (Previously presented) The method of claim 36, wherein the subject is a human.
43. (Currently amended) A method of treating tumor in a subject, comprising the step of administering to the subject ~~an effective amount of~~ 5 mg/kg to 10 mg/kg VNP40101M and ~~an effective amount of~~ about 70 mg/kg fludarabine, wherein the amounts of VNP40101M and fludarabine administered provide a reduction in tumor growth that is larger than that achieved by administering either VNP40101M or fludarabine individually.
44. (Previously presented) The method of claim 43, wherein the tumor is solid malignant tumor, leukemia or lymphoma.

Applicants : KING et al.
USSN : 10/593,217
Filed : September 15, 2006
Examiner : Krishnan Ganapathy
Page : 5

Atty. Dkt. No. : 891-A-PCT-US
Art Unit : 1623
Date of office action: December 3, 2008
Date of response : March 3, 2009

45. (Previously presented) The method of claim 43, wherein VNP40101M and fludarabine are administered concurrently or sequentially.
46. (Previously presented) The method of claim 43, wherein VNP40101M and fludarabine are administered intravenously, subcutaneously, or orally.
47. (Previously presented) The method of claim 44, wherein the leukemia is acute myelogenous leukemia.
48. (Previously presented) The method of claim 43, wherein the subject is a human.